{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 40,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a stacked bar chart to show revenue composition over six quarters and a bulleted list to explain the underlying business dynamics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/23",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Total Revenue $3.5bn, +10% pro forma H1 2022",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc06339d-31e9-41bc-ba7d-77e122e80a25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.51,
        "y": 0.35
      },
      "kind": "list",
      "text": "Durable growth C5 franchise (Soliris + Ultomiris), +9%; Soliris, 2% slowing growth; Ultomiris, +31% continued conversion; Strensiq, +18% strong US demand; Koselugo, >2x performance driven by expansion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec7bdb81-ab53-4e72-9e52-8382d1f47d27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Pro forma growth rates... gMG = generalised myasthenia gravis, PNH = paroxysmal nocturnal haemoglobinuria, aHUS = atypical haemolytic uraemic syndrome.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a2eb8f7-1cf9-4761-8ada-9923bcfb799e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Strong initial demand for Ultomiris in gMG from both switch and naïve patients",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05611790-fbec-407f-9937-a45478cf9531",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Rare Disease: H1 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8abef026-36a7-4ed8-80e4-47a50b69456b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "453c2b91-5c3d-4a29-b417-90a2ffb44cc6",
      "evidence": "chart/bar-stacked: Total Revenue $3.5bn, +10% pro forma H1 2022",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a580e542-4ecb-4b8c-ac79-8c3f459d8a27",
      "evidence": "list/bullet: Durable growth C5 franchise (Soliris + Ultomiris), +9%; Soliris, 2% slowing growth; Ultomiris, +31% continued conversion; Strensiq, +18% strong US demand; Koselugo, >2x performance driven by expansion",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "action-titles",
      "slug": null,
      "matchId": "72c037e6-9004-41cd-944c-ceec74eb9c31",
      "evidence": "The slide uses a descriptive, thesis-driven headline to summarize the key takeaway.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}